Overview

A Study to Evaluate the Safety, Tolerance, Pharmacokinetics, and Preliminary Antineoplastic Activity of AK132 in Advanced Malignant Solid Tumor

Status:
Not yet recruiting
Trial end date:
2026-07-24
Target enrollment:
Participant gender:
Summary
This is A Phase I Study to Evaluate the Safety, Tolerance, Pharmacokinetics, and Preliminary Antineoplastic Activity of The anti-CLDN18.2 and CD47 Bispecific Antibody AK132 in Advanced Malignant Solid Tumor
Phase:
Phase 1
Details
Lead Sponsor:
Akeso